Ilaria Lodola, Ferdinando D'Amico, Silvio Danese, Tommaso Lorenzo Parigi
{"title":"Artificial intelligence in inflammatory bowel disease endoscopy - a review of current evidence and a critical perspective on future challenges.","authors":"Ilaria Lodola, Ferdinando D'Amico, Silvio Danese, Tommaso Lorenzo Parigi","doi":"10.1177/17562848251350896","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a chronic and relapsing immune-mediated condition with a rising global prevalence. Endoscopic diagnosis, monitoring and surveillance currently depend on individual endoscopists, introducing subjectivity, variability, delays and potential diagnostic discrepancies. Artificial intelligence (AI) is poised to transform these processes. To date, most AI applications have focused on ulcerative colitis (UC) severity assessment, demonstrating promising results in replicating human evaluation, standardizing severity evaluation and facilitating the application of more complex scoring systems. Research into AI for Crohn's disease (CD) has lagged behind UC, due to challenges such as disease heterogeneity and transmural extension; nevertheless, significant progress has been made to automate capsule endoscopy readings for CD. Beyond the grading of disease severity, AI is also being explored for tasks such as identifying dysplastic lesions, differentiating IBD from other conditions, assessing intestinal barrier permeability, guiding treatment decisions and integrating data from multiple omics, though studies in these areas remain exploratory. This review examines the current landscape of AI applications in IBD endoscopy, summarizes key studies in the field and explores the future potential of AI in IBD care.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251350896"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256760/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848251350896","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Inflammatory bowel disease (IBD) is a chronic and relapsing immune-mediated condition with a rising global prevalence. Endoscopic diagnosis, monitoring and surveillance currently depend on individual endoscopists, introducing subjectivity, variability, delays and potential diagnostic discrepancies. Artificial intelligence (AI) is poised to transform these processes. To date, most AI applications have focused on ulcerative colitis (UC) severity assessment, demonstrating promising results in replicating human evaluation, standardizing severity evaluation and facilitating the application of more complex scoring systems. Research into AI for Crohn's disease (CD) has lagged behind UC, due to challenges such as disease heterogeneity and transmural extension; nevertheless, significant progress has been made to automate capsule endoscopy readings for CD. Beyond the grading of disease severity, AI is also being explored for tasks such as identifying dysplastic lesions, differentiating IBD from other conditions, assessing intestinal barrier permeability, guiding treatment decisions and integrating data from multiple omics, though studies in these areas remain exploratory. This review examines the current landscape of AI applications in IBD endoscopy, summarizes key studies in the field and explores the future potential of AI in IBD care.
期刊介绍:
Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of gastroenterology and hepatology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.